Navigation Links
KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
Date:6/24/2009

DURHAM, N.C., June 24 /PRNewswire/ -- KBI Biopharma, Inc. (KBI) announced today that it has started the process of performing cell line generation with Crucell's PER.C6(R) human cell line platform, pursuant to the Agreement announced by Crucell, The Netherlands, on May 6, 2009. Under that agreement, KBI joins the Vendor Network as a U.S.-based pre-approved cell line generation partner for licensees of the PER.C6(R) cell lines.

KBI is a leading biopharmaceutical contract services company providing fully integrated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. KBI, based in Durham, NC, applies cell line generation, extensive protein characterization, manufacturing process development and clinical biomanufacturing capabilities to accelerate and optimize its clients' drug development programs. This comprehensive and integrated suite of services enables clients to bring drugs to market faster and more efficiently. KBI is recognized for its track record in advancing its clients' drug programs by developing scalable, robust processes that result in more stable, active products.

Joseph McMahon, President and CEO of KBI Biopharma notes, "We recognize the significant market interest in and adoption of this technology and are very pleased to now offer cell line generation using the PER.C6(R) cell line." Mr. McMahon added, "Our KBI scientific team has extensive experience producing cell lines in microbial, insect and mammalian systems and are very pleased that Crucell and DSM have recognized our expertise by selecting KBI as a Partner for their Vendor Network."

KBI is now proud to offer the PER.C6(R) technology as part of its extensive capabilities in cell line development.

Other terms of the agreement were not disclosed.

About KBI Biopharma, Inc.

KBI Biopharma, located in Durham, NC, is a leading contract development organization for the biopharmaceutical industry, working with companies across the globe focused on protein-based products. KBI delivers expert and integrated biophysical and biochemical protein characterization, formulation and process development and cGMP manufacturing of recombinant protein Active Pharmaceutical Ingredients (API's). For additional information about KBI Biopharma please visit www.kbibiopharma.com.

PER.C6(R) technology

Crucell's PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins, including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6(R) technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions. By employing the PER.C6(R) human cell line with a proprietary process technology, a record yield of over 27 grams per liter in the production of IgG antibodies has been achieved.


'/>"/>
SOURCE KBI Biopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, announces a ... in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree ... products targeting the needs of consumers who are incorporating medical marijuana into their ... Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s ...
(Date:10/6/2017)... ... 2017 , ... The HealthTech Venture Network (HTVN) is proud ... annual Conference where founders, investors, innovative practitioners and collaborators are invited to a ... early stage digital health and med tech companies. , This day-long event will ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):